Action 603590 BEIJING KONRUNS PHARMACEUTICAL CO.,LTD.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Beijing Konruns Pharmaceutical Co.,Ltd.

Actions

603590

CNE1000036K3

Cours en clôture Shanghai S.E.
Autres places de cotation
 00:00:00 16/05/2024 		Varia. 5j. Varia. 1 janv.
30,17 CNY -0,36% Graphique intraday de Beijing Konruns Pharmaceutical Co.,Ltd. -5,51% -20,77%
25/04 Beijing Konruns Pharmaceutical Co. publie ses résultats pour le premier trimestre clos le 31 mars 2024 CI
08/04 Beijing Konruns Pharmaceutical Co. publie ses résultats pour l'exercice clos le 31 décembre 2023 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Konruns Pharma Enrolls First Subject in Phase 3 Study of Cancer Drug
Beijing Konruns Pharmaceutical Gets Nod to Test KC1036 Tablets as Esophagus Cancer Treatment
Konruns Pharmaceutical Gets Clearance for Clinical Trial of Sarcoma Treatment
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Certain A Shares of Beijing Konruns Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 27-AUG-2023.
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Chengdu WestGene Biomedical Technology Co., Ltd. announced that it has received $63.25 million in funding from Qingdao Honline Huaxin Asset Management Co., Ltd., Beijing Konruns Pharmaceutical Co.,Ltd., Hangzhou Tigermed Consulting Co., Ltd, Chengdu Guanghua Wutong Equity Investment Fund Management Co., Ltd., Yingke Innovation Asset Management Co., Ltd.
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Chengdu WestGene Biomedical Technology Co., Ltd. announced that it has received $21.45 million in funding from Qingdao Honline Huaxin Asset Management Co., Ltd.,Yingke Innovation Asset Management Co., Ltd.,Chengdu Guanghua Wutong Equity Investment Fund Management Co., Ltd. and Hangzhou Tigermed Consulting Co., Ltd.
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
Certain A Shares of Beijing Konruns Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 27-AUG-2022.
Beijing Konruns Pharmaceutical Co.,Ltd. cancelled the transaction announced on March 1, 2021
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
Tranche Update on Beijing Konruns Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on January 21, 2021.
Beijing Konruns Pharmaceutical Co.,Ltd.'s Equity Buyback announced on January 21, 2021, has expired with 2,273,523 shares, representing 1.44% for CNY 79.31 million.
Tranche Update on Beijing Konruns Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on January 21, 2021.
Beijing Konruns Pharmaceutical Co.,Ltd. completed the acquisition of 13.70% stake in Beijing Konruns Biotechnology Co., Ltd. from NT Pharma Pacific Company Limited.
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 603590
  4. Actualités Beijing Konruns Pharmaceutical Co.,Ltd.
  5. Autres langues